Sana Biotechnology (SANA) Gains from Investment Securities (2020 - 2026)

Sana Biotechnology has reported Gains from Investment Securities for 7 years, with the latest figure at $10.7 million in Q1 2026.

• Quarterly Gains from Investment Securities rose 476.45% year-over-year to $10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.6 million (up 972.28% YoY) and the FY2025 annual result came in at $14.8 million, up 2411.91% from the prior year.
• Gains from Investment Securities rose to $10.7 million in Q1 2026 per SANA's latest filing, from $8.6 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $10.7 million in Q1 2026 and troughed at -$58.6 million in Q3 2023.
• A 5-year average of -$505117.6 and a median of $3.4 million in 2024 frame the typical range for Gains from Investment Securities.
• The widest YoY moves for Gains from Investment Securities: up 1134.09% in 2023, down 606.02% in 2023.
• Over 5 years, Gains from Investment Securities stood at $9.2 million in 2022, then tumbled by 30.26% to $6.4 million in 2023, then slumped by 144.78% to -$2.9 million in 2024, then surged by 396.99% to $8.6 million in 2025, then advanced by 25.28% to $10.7 million in 2026.
• According to Business Quant data, Gains from Investment Securities over the past three periods registered $10.7 million, $8.6 million, and $2.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.